Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1627
    -0.0056 (-0.48%)
     
  • GBP/USD

    1.2378
    -0.0060 (-0.48%)
     
  • Bitcoin GBP

    51,687.71
    +362.04 (+0.71%)
     
  • CMC Crypto 200

    1,334.09
    +21.47 (+1.57%)
     
  • S&P 500

    4,972.92
    -38.20 (-0.76%)
     
  • DOW

    37,861.34
    +85.96 (+0.23%)
     
  • CRUDE OIL

    83.06
    +0.33 (+0.40%)
     
  • GOLD FUTURES

    2,407.60
    +9.60 (+0.40%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Elisabeth Svanberg Is The of Swedish Orphan Biovitrum AB (publ) (STO:SOBI) And They Just Spent kr155k On Shares

Even if it's not a huge purchase, we think it was good to see that Elisabeth Svanberg, a Swedish Orphan Biovitrum AB (publ) (STO:SOBI) insider, recently shelled out kr155k to buy stock, at kr155 per share. While that isn't the hugest buy, it actually boosted their shareholding by 385%, which is good to see.

See our latest analysis for Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when CEO & President Guido Oelkers bought kr9.3m worth of shares at a price of kr190 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being kr164). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

ADVERTISEMENT

While Swedish Orphan Biovitrum insiders bought shares last year, they didn't sell. The chart below shows insider transactions (by individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

OM:SOBI Recent Insider Trading, November 12th 2019
OM:SOBI Recent Insider Trading, November 12th 2019

Swedish Orphan Biovitrum is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Swedish Orphan Biovitrum

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From looking at our data, insiders own kr46m worth of Swedish Orphan Biovitrum stock, about 0.1% of the company. We prefer to see high levels of insider ownership.

What Might The Insider Transactions At Swedish Orphan Biovitrum Tell Us?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. Insiders likely see value in Swedish Orphan Biovitrum shares, given these transactions (along with notable insider ownership of the company). Of course, the future is what matters most. So if you are interested in Swedish Orphan Biovitrum, you should check out this free report on analyst forecasts for the company.

Of course Swedish Orphan Biovitrum may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.